Enhanced transfection efficiency and targeted delivery of self-assembling h-R3-dendriplexes in EGFR-overexpressing tumor cells

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26177-26191

  Li, Jun ^a   Li, Shengnan ^b,c   Xia, Songyun ^c   Feng, Jinfeng ^a   Zhang, Xuedi ^a   Hao, Yanli ^a   Chen, Lei ^b,c   Zhang, Xiaoning ^a,d  

^a Tsinghua University   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c NAVY GENERAL HOSPITAL   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

EGFR; Gene therapy; h R3; PAMAM; Targeted delivery

Indexed keywords

DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; POLYAMIDOAMINE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PAMAM STARBURST; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL DEATH; CELL GROWTH; CELL POPULATION; CELL VIABILITY; DRUG CYTOTOXICITY; ENDOCYTOSIS; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; P53 GENE; PARTICLE SIZE; PROTEIN EXPRESSION; SURFACE PROPERTY; ZETA POTENTIAL; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HEK293 CELL LINE; HEP-G2 CELL LINE; IMMUNOLOGY; LIVER NEOPLASMS, EXPERIMENTAL; MCF-7 CELL LINE; METABOLISM; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PROCEDURES; TIME FACTOR; TUMOR VOLUME; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DENDRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944463281     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4614     Document Type: Article

References (48)

1. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4:581-393.
2. Chen H, Liu X, Dou Y, He B, Liu L, Wei Z, Li J, Wang C, Mao C, Zhang J, Wang G. A pH-responsive cyclodextrinbased hybrid nanosystem as a nonviral vector for gene delivery. Biomaterials. 2013; 34:4159-4172.
3. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12:967-977.
4. Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED, Sehgal A, Querbes W, Zurenko CS, Jayaraman M, Peng CG, Charisse K, Borodovsky A, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nano. 2012; 7:389-393.
5. Mintzer MA, Simanek EE. Nonviral Vectors for Gene Delivery. Chem Rev. 2008; 109:259-302.
6. Gao K, Huang L. Nonviral Methods for siRNA Delivery. Mol Pharmaceutics. 2009; 6:651-658.
7. Guo S, Huang Y, Wei T, Zhang W, Wang W, Lin D, Zhang X, Kumar A, Du Q, Xing J, Deng L, Liang Z, Wang PC, et al. Amphiphilic and biodegradable methoxy polyethylene glycol-block-(polycaprolactone-graft-poly(2-(dimethylamino)ethyl methacrylate)) as an effective gene carrier. Biomaterials. 2011; 32:879-889.
8. Ong ZY, Fukushima K, Coady DJ, Yang Y-Y, Ee PLR, Hedrick JL. Rational design of biodegradable cationic polycarbonates for gene delivery. J Controlled Release. 2011; 152:120-126.
9. Chen CJ, Wang JC, Zhao EY, Gao LY, Feng Q, Liu XY, Zhao ZX, Ma XF, Hou WJ, Zhang LR, Lu WL, Zhang Q. Self-assembly cationic nanoparticles based on cholesterolgrafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials. 2013; 34:5303-5316.
10. Zhang W, Cheng Q, Guo S, Lin D, Huang P, Liu J, Wei T, Deng L, Liang Z, Liang XJ, Dong A. Gene transfection efficacy and biocompatibility of polycation/DNA complexes coated with enzyme degradable PEGylated hyaluronic acid. Biomaterials. 2013; 34:6495-6503.
11. Liu T, Yu X, Kan B, Guo Q, Wang X, Shi S, Guo G, Luo F, Zhao X, Wei Y, Qian Z. Enhanced gene delivery using biodegradable poly(ester amine)s (PEAs) based on low-molecular-weight polyethylenimine and poly(epsiloncaprolactone)-pluronic-poly(epsilon-caprolactone). J Biomed Nanotechnol. 2010; 6:351-359.
12. Shi S, Zhu X, Guo Q, Wang Y, Zuo T, Luo F, Qian Z. Selfassembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: synthesis and characterization in vitro. Int J Nanomedicine. 2012; 7:1749-1759.
13. Tiram G, Scomparin A, Ofek P, Satchi-Fainaro R. Interfering cancer with polymeric siRNA nanomedicines. J Biomed Nanotechnol. 2014; 10:50-66.
14. Shi S, Shi K, Tan L, Qu Y, Shen G, Chu B, Zhang S, Su X, Li X, Wei Y, Qian Z. The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin. Biomaterials. 2014; 35:4536-4547.
15. Perez AP, Romero EL, Morilla MJ. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm. 2009; 380:189-200.
16. Svenson S, Tomalia DA. Dendrimers in biomedical applications-eflections on the field. Adv Drug Deli Rev. 2012; 64:102-115.
17. Figueroa ER, Lin AY, Yan J, Luo L, Foster AE, Drezek RA. Optimization of PAMAM-gold nanoparticle conjugation for gene therapy. Biomaterials. 2014; 35:1725-34.
18. Won Y-W, Lee M, Kim HA, Nam K, Bull DA, Kim SW. Synergistically Combined Gene Delivery for Enhanced VEGF Secretion and Antiapoptosis. Mol Pharmaceutics. 2013; 10:3676-3683.
19. Li Y, He H, Jia X, Lu W-L, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012; 33:3899-3908.
20. Somani S, Blatchford DR, Millington O, Stevenson ML, Dufès C. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J Controlled Release. 2014; 188:78-86.
21. Silpe JE, Sumit M, Thomas TP, Huang B, Kotlyar A, van Dongen MA, Banaszak Holl MM, Orr BG, Choi SK. Avidity Modulation of Folate-Targeted Multivalent Dendrimers for Evaluating Biophysical Models of Cancer Targeting Nanoparticles. ACS Chem Biol. 2013; 8:2063-2071.
22. Benchaala I, Mishra MK, Wykes SM, Hali M, Kannan RM, Whittum-Hudson JA. Folate-functionalized dendrimers for targeting Chlamydia-infected tissues in a mouse model of reactive arthritis. Int J Pharm. 2014; 466:258-265.
23. Lee H, Hu M, Reilly RM, Allen C. Apoptotic Epidermal Growth Factor (EGF)-Conjugated Block Copolymer Micelles as a Nanotechnology Platform for Targeted Combination Therapy. Mol Pharmaceutics. 2007; 4:769-781.
24. Chiu S-J, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine. J Controlled Release. 2004; 97:357-369.
25. Park J, Brust TF, Lee HJ, Lee SC, Watts VJ, Yeo Y. Polydopamine-Based Simple and Versatile Surface Modification of Polymeric Nano Drug Carriers. ACS Nano. 2014; 8:3347-3356.
26. Guo Z, He B, Jin H, Zhang H, Dai W, Zhang L. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin avß3 clustering. Biomaterials. 2014; 35:6106-6117.
27. Zhang Q, Chen S, Zhuo RX, Zhang XZ, Cheng SX. Self-Assembled Terplexes for Targeted Gene Delivery with Improved Transfection. Bioconjugate Chem. 2010; 21:2086-2092.
28. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, Krengel U, Moreno E. Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation. Cancer Res. 2009; 69:5851-5859.
29. Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncology. 2009; 5:1349-1361.
30. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012; 30:1138-1143.
31. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011; 11:247-256.
32. Zhou T, Llizo A, Wang C, Xu G, Yang Y. Nanostructureinduced DNA condensation. Nanoscale. 2013; 5:8288-8306.
33. Fant K, Esbjörner EK, Lincoln P, Nordén B. DNA Condensation by PAMAM Dendrimers: Self-Assembly Characteristics and Effect on Transcription. Biochemistry. 2008; 47:1732-1740.
34. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. J Controlled Release. 2010; 141:320-327.
35. Chen CK, Jones CH, Mistriotis P, Yu Y, Ma X, Ravikrishnan A, Jiang M, Andreadis ST, Pfeifer BA, Cheng C. Poly(ethylene glycol)-block-cationic polylactide nanocomplexes of differing charge density for gene delivery. Biomaterials. 2013; 34:9688-9699.
36. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009; 8:15-23.
37. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2:347-360.
38. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11:812-818.
39. Hinrichs WLJ, Schuurmans-Nieuwenbroek NME, van de Wetering P, Hennink WE. Thermosensitive polymers as carriers for DNA delivery. J Controlled Release. 1999; 60:249-259.
40. Habib AA, Chun SJ, Neel BG, Vartanian T. Increased Expression of Epidermal Growth Factor Receptor Induces Sequestration of Extracellular Signal-Related Kinases and Selective Attenuation of Specific Epidermal Growth Factor-Mediated Signal Transduction Pathways. Mol Cancer Res. 2003; 1:219-233.
41. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Comm. 2007; 353:26-32.
42. Khalil IA, Kogure K, Akita H, Harashima H. Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery. Pharmaco Rev. 2006; 58:32-45.
43. Sakurai Y, Hatakeyama H, Sato Y, Akita H, Takayama K, Kobayashi S, Futaki S, Harashima H. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials. 2011; 32:5733-5742.
44. Lechardeur D, Verkman AS, Lukacs GL. Intracellular routing of plasmid DNA during non-viral gene transfer. Adv Drug Deli Rev. 2005; 57:755-767.
45. Nichols JW, Bae YH. EPR: Evidence and fallacy. J Controlled Release. 2014; 190:451-464.
46. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Brit J Cancer. 2001; 85:1813-1823.
47. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
48. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer drugs. 1992; 3:311-321.